We randomly assigned patients in a 1:1:1 ratio with an interactive voice-web response system to receive 40 mg pasireotide long-acting release once every 28 days for 24 weeks , 60 mg pasireotide long-acting release once every 28 days for 24 weeks , or continued treatment with octreotide or lanreotide ( active control ) .